V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220008895 | 220011958 | 1.95 | 56.25 | Curative (C) | 2017-06-25 | 2017-08-06 | Triple / Double Intrathecal Therapy | Y | N | 220035454 | FLUDARABINE + MELPHALAN |
| 220008896 | 220016452 | 1.63 | 70 | Curative (C) | 2014-12-21 | 2015-01-01 | RUXOLITINIB | 2 | N | 220035456 | CYTARABINE + DAUNORUBICIN + ETOPOSIDE |
| 220008897 | 220016452 | 1.57 | -1 | Palliative (P) | null | 2015-11-10 | Docetaxel 100mg/m2 (21 day) | N | N | 220035456 | DABRAFENIB + TRAMETINIB |
| 220008898 | 220016452 | 1.58 | 92.5 | Palliative (P) | 2016-02-23 | 2016-02-23 | OCTREOTIDE | 02 | N | 220035456 | LANREOTIDE |
| 220008899 | 220021325 | 1.67 | 85 | Adjuvant (A) | 2017-07-06 | 2017-11-23 | CVP R | 2 | N | 220035465 | CISPLATIN + FLUOROURACIL |
| 220008900 | 220021325 | 1.57 | 68 | Palliative (P) | 2014-12-25 | 2014-12-29 | Irinotecan + Modified De Gramont | N | N | 220035465 | CAPECITABINE |
| 220008901 | 220022034 | 0 | 0 | Palliative (P) | null | 2016-12-16 | ECF | N | N | 220035470 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 220008902 | 220003596 | null | 86 | null | 2015-02-24 | 2015-03-10 | DABRAFENIB + TRAMETINIB | N | Y | 220035471 | IPILIMUMAB |
| 220008903 | 220003596 | null | 76.5 | Palliative (P) | null | 2014-02-21 | RUXOLITINIB | null | N | 220035471 | DOCETAXEL |
| 220008904 | 220003597 | 1.69 | 63.9 | Palliative (P) | null | 2013-03-22 | Cisplatin +Fluorouracil (3 wk) | null | null | 220035476 | BEVACIZUMAB + OXALIPLATIN + MdG |
| 220008905 | 220011960 | 1.6 | 119.4 | Palliative (P) | null | 2017-05-21 | FEC | null | N | 220035479 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 220008906 | 220011960 | 1.78 | 43.9 | Curative (C) | 2013-02-27 | 2013-05-01 | CISPLATIN + FLUOROURACIL | N | N | 220035479 | FBC |
| 220008907 | 220011960 | 1.8 | 66.35 | Palliative (P) | 2014-04-24 | 2014-04-24 | Dacarbazine | N | N | 220035479 | CAPECITABINE + CISPLATIN |
| 220008908 | 220020502 | 0 | 68.5 | Palliative (P) | 2017-08-16 | 2017-08-16 | Busulfan Oral | 02 | N | 220035486 | RUXOLITINIB |
| 220008909 | 220020502 | 1.61 | 108.75 | Palliative (P) | 2013-12-13 | 2013-12-23 | Pentostatin | null | null | 220035486 | PACLITAXEL |
| 220008910 | 220003598 | 1.63 | 74.7 | Disease modification (D) | 2017-07-17 | 2017-08-06 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 220035490 | BUSULFAN + CYCLOPHOSPHAMIDE |
| 220008911 | 220003599 | 1.82 | 70.7 | Palliative (P) | 2015-11-20 | 2015-12-05 | SPIRIT TRIAL | null | N | 220035492 | CAPECITABINE + IRINOTECAN |
| 220008912 | 220003600 | 1.67 | 94 | Curative (C) | 2013-10-24 | 2013-10-24 | Cyclophosphamide TBI Allograft | 02 | N | 220035497 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220008913 | 220003601 | null | 87 | Palliative (P) | 2013-09-24 | 2013-09-28 | DOXORUBICIN | N | N | 220035503 | PACLITAXEL |
| 220008914 | 220003601 | 1.83 | 75.7 | null | 2013-02-25 | 2013-02-26 | Ipilimumab | N | N | 220035503 | DOCETAXEL |
| 220008915 | 220003601 | 1.67 | 88.5 | Palliative (P) | 2014-07-20 | 2014-07-20 | Cisplatin + Doxorubicin | N | N | 220035503 | CISPLATIN + PEMETREXED |
| 220008916 | 220003601 | null | null | Adjuvant (A) | null | 2013-03-03 | Capecitabine (21days) + Carboplatin | null | null | 220035503 | FEC |
| 220008917 | 220003601 | null | null | null | 2017-06-10 | 2017-06-10 | Fludarabine + Melphalan RIC Allo | N | N | 220035503 | MELPHALAN |
| 220008918 | 220003602 | null | 68.3 | Palliative (P) | null | 2015-11-15 | Vemurafenib | null | Y | 220035511 | CISPLATIN + FLUOROURACIL |
| 220008919 | 220011962 | null | 66.4 | Palliative (P) | null | 2015-01-01 | CTD (Thalidomide 100mg) | null | null | 220035513 | ECF |
| 220008920 | 220011962 | 1.74 | null | Palliative (P) | 2016-02-20 | 2016-02-21 | DABRAFENIB | 2 | N | 220035513 | DABRAFENIB + TRAMETINIB |
| 220008921 | 220019031 | 1.64 | 85 | Palliative (P) | 2014-07-02 | 2014-07-09 | Docetaxel 75mg/m2 (21 day) | N | N | 220035519 | IPILIMUMAB + NIVOLUMAB |
| 220008922 | 220003603 | 1.62 | 0 | Curative (C) | 2017-02-21 | 2017-02-21 | UKALL14- Ph 1 Induction | 02 | N | 220035521 | UKALL2014 |
| 220008923 | 220003604 | 1.79 | 79 | Palliative (P) | 2018-04-09 | 2018-04-24 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 220035523 | CAPECITABINE |
| 220008924 | 220003605 | 0 | 69.9 | Neo-adjuvant (N) | 2016-04-28 | 2016-04-28 | UKALL14- Ph 1 Induction + Imatinib | 02 | N | 220035527 | BENDAMUSTINE + THALIDOMIDE |
| 220008925 | 220003605 | 1.58 | 70.95 | Palliative (P) | 2013-04-22 | 2013-04-23 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 2 | Y | 220035527 | PEMETREXED |
| 220008926 | 220003605 | 0 | 62.5 | Curative (C) | 2013-01-31 | 2013-02-07 | IDARUBICIN | 02 | N | 220035527 | IDARUBICIN + MITOXANTRONE + TRETINOIN |
| 220008927 | 220003606 | null | null | Disease modification (D) | 2014-07-10 | 2014-07-11 | FEC 100 | N | N | 220035531 | RUXOLITINIB |
| 220008928 | 220003606 | null | null | null | 2013-09-04 | 2013-09-04 | UKALL14- Ph 2 Induction | N | N | 220035531 | IVE |
| 220008929 | 220003607 | 1.72 | 88.3 | null | 2014-10-15 | 2014-10-16 | Mitoxantrone | N | N | 220035533 | FLUDARABINE |
| 220008930 | 220003608 | null | null | Disease modification (D) | 2013-12-15 | 2013-12-16 | Capecitabine + Cisplatin + RT | 02 | N | 220035534 | CYTARABINE INTRATHECAL |
| 220008931 | 220003609 | 0 | 0 | Curative (C) | 2016-10-05 | 2016-10-05 | Chlorambucil | 02 | N | 220035535 | CHOP R |
| 220008939 | 220021780 | 1.72 | 97.6 | Palliative (P) | 2016-09-07 | 2016-09-28 | ATG + Busulfan + Fludarabine | N | N | 220035551 | BOSUTINIB |
| 220008940 | 220003612 | 1.64 | 80.5 | Palliative (P) | 2015-06-28 | 2016-04-16 | AML LI-1 Trial | N | N | 220035556 | CISPLATIN + PEMETREXED |
| 220008941 | 220003613 | 1.65 | 101.8 | Curative (C) | 2017-08-26 | 2017-09-16 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 220035563 | ALEMTUZUMAB + BUSULFAN + CYCLOPHOSPHAMIDE |
| 220008942 | 220003614 | null | 70.95 | Adjuvant (A) | null | 2016-12-13 | Cytarabine intrathecal | null | null | 220035566 | RUXOLITINIB |
| 220008943 | 220003615 | 1.73 | 80 | Palliative (P) | 2016-03-28 | 2016-03-28 | Cetuximab 7 day (>Cycle 2) | N | N | 220035568 | DABRAFENIB + TRAMETINIB |
| 220008944 | 220003616 | null | 69.8 | null | 2016-02-18 | 2016-02-18 | ANAGRELIDE | null | N | 220035570 | BUSULPHAN |
| 220008945 | 220003617 | 1.77 | 74.5 | Palliative (P) | 2016-09-19 | 2016-10-09 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220035571 | DOXORUBICIN + IFOSFAMIDE |
| 220008946 | 220003618 | 1.73 | 76 | Palliative (P) | 2016-04-21 | 2016-04-21 | Cisplatin | N | N | 220035575 | TEMOZOLOMIDE + RT |
| 220008947 | 220003618 | 1.6 | null | Curative (C) | 2017-12-24 | 2018-01-07 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | null | null | 220035575 | IDARUBICIN |
| 220008948 | 220003619 | 1.69 | 56.6 | Palliative (P) | 2017-03-15 | 2017-03-15 | BOSUTINIB | N | N | 220035577 | VEMURAFENIB |
| 220008949 | 220003619 | 1.67 | 49 | Palliative (P) | 2015-02-03 | 2015-03-19 | TRASTUZUMAB EMTANSINE | 02 | N | 220035577 | DABRAFENIB + TRAMETINIB |
| 220008950 | 220003620 | 1.84 | 73.3 | Curative (C) | 2017-11-29 | 2017-11-29 | Capecitabine (21 day) + Irinotecan | null | N | 220035580 | LI-1 TRIAL |
| 220008951 | 220003620 | 1.83 | 58 | Disease modification (D) | 2013-08-04 | 2013-08-04 | Cisplatin + Pemetrexed | 2 | N | 220035580 | MIDOSTAURIN |